Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > GW Pharmaceuticals Plc ADS (GWPH)

Why $GWPH was down today:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Triple9 Member Profile
Followed By 68
Posts 1,188
Boards Moderated 4
Alias Born 01/13/17
160x600 placeholder
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
Cannabis Biotechs Taking Leading Stance in Global Marijuana Market "NetworkNewsWire" - 9/12/2017 8:45:00 AM
GW Pharmaceuticals to Present at Upcoming Investor Conferences "GlobeNewswire Inc." - 9/5/2017 12:09:45 PM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing "InvestorsHub NewsWire" - 8/30/2017 10:29:33 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 "InvestorsHub NewsWire" - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code "InvestorsHub NewsWire" - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference "InvestorsHub NewsWire" - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market "InvestorsHub NewsWire" - 8/22/2017 1:27:13 AM
PURA - Puration Advances $100 Million Revenue Strategy As Marijuana Justice Act Is Proposed To Congress "InvestorsHub NewsWire" - 8/8/2017 10:21:03 AM
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2017 Financial Results and Operational Progress "GlobeNewswire Inc." - 8/7/2017 4:05:00 PM
PURA Gears Up To Enter Marijuana Pharmaceutical Market Competing With Likes of GWPH MJNA and CBIS "InvestorsHub NewsWire" - 8/4/2017 11:47:31 AM
Biotech Players Lead the Growth Charge in the Legal Cannabis Market "NetworkNewsWire" - 7/27/2017 8:45:00 AM
PURA - Puration Presents Strategy For $100 Million In Revenue From Recent Grow Operation Acquisition "InvestorsHub NewsWire" - 7/26/2017 8:30:00 AM
GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017 "GlobeNewswire Inc." - 7/24/2017 3:00:19 PM
What it Takes to Stand Out from the Crowd in the Legalized Marijuana Space "NetworkNewsWire" - 7/12/2017 8:45:00 AM
PURA Announces $1.2 Million Sales Contract Adding To Existing Cannabis Extraction Business With Expansion Potential to $16 M "InvestorsHub NewsWire" - 7/11/2017 10:00:27 AM
Puration Announces $1.2 Million Sales Contract Adding to Existing Cannabis Extraction Business With Expansion Potential to $1... "PR Newswire (US)" - 7/11/2017 8:30:00 AM
PURA Technical Trading BULLISH Trend Highlighted By AmericanBulls "InvestorsHub NewsWire" - 6/30/2017 11:28:36 AM
PURA Stands Out In Marijuana Sector Signaling BULLISH While Other Sector Stocks Are Still Looking For Momentum "InvestorsHub NewsWire" - 6/29/2017 10:46:31 AM
PURA - Pharmaceutical Advancements in Medicinal Marijuana Continue to Evolve While Producing Higher Quality Cannabinoid Extra... "InvestorsHub NewsWire" - 6/23/2017 10:03:32 AM
PURA - Puration Announces Pending Acquisition Of $1 Million Annual Revenue Grow Operation With Plan To Expand To $16 Million "InvestorsHub NewsWire" - 6/22/2017 9:05:45 AM
Triple9   Friday, 09/29/17 04:42:54 PM
Re: None
Post # of 4859 
Why $GWPH was down today:

GW Pharma slips 15% premarket on Zogenix's successful late-stage study of ZX008 in Dravet

Sep. 29, 2017 7:48 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor

GW Pharmaceuticals (NASDAQ:GWPH) is down 15% premarket, albeit on only 779 shares, in apparent response to Zogenix's announcement of positive Phase 3 results for Dravet syndrome candidate ZX008.

GW's late-stage candidate for Dravet is Epidiolex (cannabidiol).

Previously: Zogenix's lead candidate ZX008 successful in late-stage Dravet study (Sept. 29)

Previously: GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome (April 21, 2015)

I dislike linking Seeking Alpha articles but this one seems to be dead on.

Know What You Own. My posts should not be construed as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist